
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
INSTRUMENT ONLY TEMPLATE
A. 510(k) Number: K060656
B. Purpose for Submission: Traditional 510(k)
C. Manufacturer and Instrument Name: Sysmex America, Inc. Sysmex® XS
Automated Hematology Analyzer series (XS-100i and XS-800i).
D. Type of Test or Tests Performed: 21 Complete Blood Count analysis parameters in
whole blood.
E. System Descriptions:
1. Device Description: The XS is an automated hematology analyzer which consists
of three principal units: (1) Main unit which aspirates, dilutes, mixes and analyzes
whold blood samples; (2) Auto Loader on the XS-1000i that supplies samples to
the Main Unit automatically ; (3) IPU (Information Processing Unit) which
processes data from the Main Unit and provides the operator interface with the
system. The XS-1000i and XS-800i are the same instruments except that the XS-
1000i has the ability to install an auto loader and the XS-800i uses a manual mode
only.
2. Principles of Operation: The XS performs hematology analyses using the
following methods: Sheath Flow DC Detection Method, Flow Cytometry
Methods using a Semiconductor Laser and SLS-hemoglobin method. Blood cells
pass through the aperture of the detector surrounded by a sheath fluid using the
sheath flow method. The principle of flow cytometry is also used. A
semiconductor laser beam is emitted to the blood cells passing through the flow
cell. The forward scattered light is received by the photodiode, and the lateral
scattered light and lateral fluorescent light are received by the photo multiplier
tube. This light is converted into electrical pulses, thus making it possible to
obtain blood cell information. Hemoglobin is measured with the SLS-hemoglobin
method using Sodium Lauryl Sulfate, which is an analysis method used in
previous Sysmex instrumentation.
3. Modes of Operation: Sampler Mode, Capillary Mode, and Manual Mode with
XS-1000i and Manual Mode and Capillary Mode with XS-800i.
4. Specimen Identification: Barcode only with XS-1000i when Sampler is
connected.
5. Specimen Sampling and Handling: Sampler Mode, Capillary Mode, and Manual
Mode with XS-1000i and Manual Mode and Capillary Mode with XS-800i.
1

--- Page 2 ---
6. Calibration: Automatic and manual calibration using fresh normal blood.
7. Quality Control: Commercial control blood is used and analyzed using X-bar
control and L-J (Levy-Jennings) Control programs.
8. Software: Comprehensive software documentation at a Moderate Level of
Concern was provided by Sysmex.
FDA has reviewed applicant’s Hazard Analysis and Software Development
processes for this line of product types:
Yes__X____ or No________
F. Regulatory Information:
1. Regulation section: 21 CFR 864.5220. Automated differential cell counter
2. Classification: Class II
3 Product code: GKZ
4. Panel: Hematology (81)
G. Intended Use:
1. Indication(s) for Use: The Sysmex XS is an automated hematology analyzer for in
vitro diagnostic use in clinical laboratories.
2. Special Conditions for Use Statement(s): N/A
H. Substantial Equivalence Information
1. Predicate Device Name(s) and 510(k) numbers:
Sysmex XT-Series: K021241, Sysmex XE-2100: K992875
2. Comparison with Predicate Device:
Similarities
Item Device Predicate
Intended Use Automated blood cell XT-Series and XE-2100:
analyzer. Same.
Sample Type Whole Blood XT-Series and XE-2100:
Same
2

[Table 1 on page 2]
Similarities								
	Item			Device			Predicate	
Intended Use
Sample Type			Automated blood cell
analyzer.
Whole Blood			XT-Series and XE-2100:
Same.
XT-Series and XE-2100:
Same		

--- Page 3 ---
Similarities
Item Device Predicate
Bar Code Yes XT-Series and XE-2100:
Same
Differences
Item Device Predicate
Sample Volume 20µL, Auto loader mode XT-Series: 150µL, Cap
20µL, Manual mode piercer mode
20µL, Capillary dilution 85µL, Manual mode
40µL, Capillary dilution
XE-2100: 200µL, Cap
piercer mode
130µL, Manual mode
40µL, Capillary dilution
Parameters WBC, Neut%/#, XT-Series: Same plus:
Lymph%/#, Mono%/#, RET%/#, IRF
Eos%/#, Baso%/#, RBC,
HGB, HCT, MCV, MCH, XE-2100: Same plus:
MCHC, RDW-CV, NRBC%/#, RET%/#,
RDW-SD, PLT, MPV IRF
Principles RBC, PLT: DC detection XT-Series:
method, RBC, PLT: DC detection
WBC: Fluorescent Flow method,
Cytometry-WBC Diff WBC: Flow Cytometry
channel using method using
semiconductor laser, semiconductor laser
HGB: SLS-Hgb method. detection method,
HGB: SLS-Hgb method
XE-2100:
RBC, PLT: Sheath-flow
DC detection method,
WBC: Flow Cytometry
method using
semiconductor laser
detection method,
HGB: SLS-Hgb method.
QC System L-J: 20 files with 180 XT-Series: L-J: 20 files
points per file. with 300 points per file.
XE-2100: L-J: 10 files
with 300 points per file.
3

[Table 1 on page 3]
Similarities								
	Item			Device			Predicate	
Bar Code			Yes			XT-Series and XE-2100:
Same		

[Table 2 on page 3]
Differences								
	Item			Device			Predicate	
Sample Volume
Parameters
Principles
QC System			20µL, Auto loader mode
20µL, Manual mode
20µL, Capillary dilution
WBC, Neut%/#,
Lymph%/#, Mono%/#,
Eos%/#, Baso%/#, RBC,
HGB, HCT, MCV, MCH,
MCHC, RDW-CV,
RDW-SD, PLT, MPV
RBC, PLT: DC detection
method,
WBC: Fluorescent Flow
Cytometry-WBC Diff
channel using
semiconductor laser,
HGB: SLS-Hgb method.
L-J: 20 files with 180
points per file.			XT-Series: 150µL, Cap
piercer mode
85µL, Manual mode
40µL, Capillary dilution
XE-2100: 200µL, Cap
piercer mode
130µL, Manual mode
40µL, Capillary dilution
XT-Series: Same plus:
RET%/#, IRF
XE-2100: Same plus:
NRBC%/#, RET%/#,
IRF
XT-Series:
RBC, PLT: DC detection
method,
WBC: Flow Cytometry
method using
semiconductor laser
detection method,
HGB: SLS-Hgb method
XE-2100:
RBC, PLT: Sheath-flow
DC detection method,
WBC: Flow Cytometry
method using
semiconductor laser
detection method,
HGB: SLS-Hgb method.
XT-Series: L-J: 20 files
with 300 points per file.
XE-2100: L-J: 10 files
with 300 points per file.		

--- Page 4 ---
Differences
Item Device Predicate
# of tests/hour Approx. 60 XT-Series: Approx 80
XE-2100: Approx 113-
150
I. Special Control/Guidance Document Referenced (if applicable): Class II Special
Controls Guidance Document: Premarket Notifications for Automated Differential
Cell Counters for Immature or Abnormal Blood Cells: final Guidance for Industry
and FDA, issued on December 4, 2001.
J. Performance Characteristics:
1. Analytical Performance:
a. Accuracy: Table 1: XS vs. XT
Parameters Correlation Regression Regression Number
Equation of
(r) (r2) Samples
WBC 1.00 0.9979 y=0.9438x+0.754 609
RBC 1.00 0.9951 y=1.0049x-0.0492 609
HGB 1.00 0.9966 y=1.0119x0.2155 609
HCT 1.00 0.9941 y=1.0163x-0.7441 609
MCV 0.99 0.9887 y=1.000x+0.2805 609
MCH 0.99 0.9772 y=0.9882+0.3751 609
MCHC 0.95 0.8951 y=0.9459+1.6856 609
PLT 1.00 0.9948 y=0.9885x-4.6694 609
RDW-SD 0.99 0.9784 y=0.9767x+0.8594 607
RDW-CV 0.99 0.9891 y=1.0111x-0.2426 607
MPV 0.82 0.6774 y=0.9247x+0.9571 574
Neut% 1.00 0.9966 y=1.0219x+0.0023 579
Lymph% 1.00 0.9992 y=0.9694x-0.064 581
Mono% 0.98 0.9702 y=0.9792x+0.0584 579
Eos% 0.98 0.9668 y=1.0474x-0.0036 595
Baso% 0.45* 0.2032 y=0.3312x+0.0261 594
4

[Table 1 on page 4]
Differences								
	Item			Device			Predicate	
# of tests/hour			Approx. 60			XT-Series: Approx 80
XE-2100: Approx 113-
150		

[Table 2 on page 4]
Parameters	Correlation
(r)	Regression
(r2)	Regression
Equation	Number
of
Samples
WBC	1.00	0.9979	y=0.9438x+0.754	609
RBC	1.00	0.9951	y=1.0049x-0.0492	609
HGB	1.00	0.9966	y=1.0119x0.2155	609
HCT	1.00	0.9941	y=1.0163x-0.7441	609
MCV	0.99	0.9887	y=1.000x+0.2805	609
MCH	0.99	0.9772	y=0.9882+0.3751	609
MCHC	0.95	0.8951	y=0.9459+1.6856	609
PLT	1.00	0.9948	y=0.9885x-4.6694	609
RDW-SD	0.99	0.9784	y=0.9767x+0.8594	607
RDW-CV	0.99	0.9891	y=1.0111x-0.2426	607
MPV	0.82	0.6774	y=0.9247x+0.9571	574
Neut%	1.00	0.9966	y=1.0219x+0.0023	579
Lymph%	1.00	0.9992	y=0.9694x-0.064	581
Mono%	0.98	0.9702	y=0.9792x+0.0584	579
Eos%	0.98	0.9668	y=1.0474x-0.0036	595
Baso%	0.45*	0.2032	y=0.3312x+0.0261	

--- Page 5 ---
*The lower r-value on the basophile% parameter is typically lower than the
other parameters due to the low frequency of the basophile cell type.
b.Precision/Reproducibility:
Table 2: Within Run Precision using blood samples (CLSI EP5)
N=20 WBC RBC HGB HCT MCV MCH MCHC PLT
Samples
#1 Mean 8.73 3.93 12.2 37.0 94.2 31.1 33.0 208.1
SD 0.14 0.03 0.1 0.4 1.0 0.2 0.4 3.8
CV% 1.65 0.72 0.6 1.0 1.0 0.6 1.3 1.8
#2 Mean 7.45 4.89 14.8 44.5 91.2 30.3 33.2 223.3
SD 0.13 0.03 0.1 0.4 1.1 0.1 0.4 4.1
CV% 1.74 0.58 0.5 0.8 1.2 0.5 1.3 1.8
#3 Mean 8.22 4.81 13.4 41.1 85.8 27.9 32.6 145.9
SD 0.11 0.02 0.0 0.4 0.8 0.1 0.4 4.3
CV% 1.36 0.38 0.4 0.9 0.9 0.5 1.1 2.9
#4 Mean 7.45 4.50 13.1 40.7 90.5 29.0 32.1 226.3
SD 0.12 0.03 0.1 0.4 1.1 0.2 0.5 3.1
CV% 1.55 0.73 0.5 1.0 1.2 0.7 1.4 1.4
#5 Mean 6.58 3.94 13.2 39.0 99.0 33.4 33.8 382.4
SD 0.13 0.05 0.1 0.5 0.9 0.4 0.4 6.1
CV% 2.03 1.22 0.4 1.3 0.9 1.1 1.3 1.6
Avg CV% 1.67 0.73 0.5 1.0 1.0 0.7 1.3 1.9
5

[Table 1 on page 5]
N=20
Samples	WBC	RBC	HGB	HCT	MCV	MCH	MCHC	PLT
#1 Mean	8.73	3.93	12.2	37.0	94.2	31.1	33.0	208.1
SD	0.14	0.03	0.1	0.4	1.0	0.2	0.4	3.8
CV%	1.65	0.72	0.6	1.0	1.0	0.6	1.3	1.8
								
#2 Mean	7.45	4.89	14.8	44.5	91.2	30.3	33.2	223.3
SD	0.13	0.03	0.1	0.4	1.1	0.1	0.4	4.1
CV%	1.74	0.58	0.5	0.8	1.2	0.5	1.3	1.8
								
#3 Mean	8.22	4.81	13.4	41.1	85.8	27.9	32.6	145.9
SD	0.11	0.02	0.0	0.4	0.8	0.1	0.4	4.3
CV%	1.36	0.38	0.4	0.9	0.9	0.5	1.1	2.9
								
#4 Mean	7.45	4.50	13.1	40.7	90.5	29.0	32.1	226.3
SD	0.12	0.03	0.1	0.4	1.1	0.2	0.5	3.1
CV%	1.55	0.73	0.5	1.0	1.2	0.7	1.4	1.4
								
#5 Mean	6.58	3.94	13.2	39.0	99.0	33.4	33.8	382.4
SD	0.13	0.05	0.1	0.5	0.9	0.4	0.4	6.1
CV%	2.03	1.22	0.4	1.3	0.9	1.1	1.3	1.6
Avg CV%	1.67	0.73	0.5	1.0	1.0	0.7	1.3	1.9

--- Page 6 ---
c. Linearity: Linearity was evaluated using a series of dilutions of residual
patient material. Replicates were measured at each level and represented the
range of linearity.
Table 3 Linearity
Parameter Range Units r2 r Slope Intercept
Tested
WBC 0-1.110 x103/µL 0.9975 1.00 1.0195 0.0034
0.080-172.40 x10³/µL 0.9993 1.00 1.0103 0.3659
0.015-448.63 x103/µL 0.9997 1.00 0.9963 1.0965
RBC 0—8.93 x106/µL 0.999 1.00 1.0096 0.0393
HGB 0—26.4 g/dL 0.9992 1.00 1.0132 0.0009
HCT 0—74.9 % 0.9959 1.00 1.0999 0.7802
0.4—64.9 % 0.9919 1.00 1.0103 1.7469
PLT 0—117 x103/µL 0.9997 1.00 0.9949 1.3913
3--5670 x103/µL 0.9981 1.00 0.9876 -41.069
d. Carryover:
Carryover was evaluated by assaying a sample with high concentration three
consecutive times followed immediately by testing a low sample consecutively 3
times. This is the method in Guidelines for the valuation of blood cell analyzers
including those used for differential leukocyte and reticulocyte counting and cell
marker applications. ISLH, January 14, 1994.
Table 4: Carryover
Parameter % Carryover % Carryover Manufacturer
Specifications
WBC 0.01 -0.02 ≤1%
RBC 0.00 -0.21 ≤1%
HGB 0.00 0.59 ≤1%
HCT 0.00 0.00 ≤1%
PLT 0.05 0.00 ≤1%
6

[Table 1 on page 6]
Parameter	Range
Tested	Units	r2	r	Slope	Intercept
WBC	0-1.110	x103/µL	0.9975	1.00	1.0195	0.0034
	0.080-172.40	x10³/µL	0.9993	1.00	1.0103	0.3659
	0.015-448.63	x103/µL	0.9997	1.00	0.9963	1.0965
						
RBC	0—8.93	x106/µL	0.999	1.00	1.0096	0.0393
						
HGB	0—26.4	g/dL	0.9992	1.00	1.0132	0.0009
						
HCT	0—74.9	%	0.9959	1.00	1.0999	0.7802
	0.4—64.9	%	0.9919	1.00	1.0103	1.7469
						
PLT	0—117	x103/µL	0.9997	1.00	0.9949	1.3913
	3--5670	x103/µL	0.9981	1.00	0.9876	-41.069

[Table 2 on page 6]
Parameter	% Carryover	% Carryover	Manufacturer
Specifications
WBC	0.01	-0.02	≤1%
RBC	0.00	-0.21	≤1%
HGB	0.00	0.59	≤1%
HCT	0.00	0.00	≤1%
PLT	0.05	0.00	≤1%

--- Page 7 ---
e. Interfering Substances:
N/A
2. Other Supportive Instrument Performance Data Not Covered Above:
Reference Values: Normal specimens from this study fell within these ranges.
Table 5: XS Reference Range Verification
Parameter Females Males Units
n=133 n=182
WBC 3.98-10.04 4.23-9.07 x103/µL
Neut% 34.0-71.1 34.0-67.9 %
Lymph% 19.3-51.7 21.8-53.1 %
Mono% 4.7-12.5 5.3-12.2 %
Eo% 0.7-5.8 0.8-7.0 %
Baso% 0.1-1.2 0.2-1.2 %
Neut# 1.56-6.13 1.78-5.38 x103/µL
Lymph# 1.18-3.74 1.32-3.57 x103/µL
Mono# 0.24-0.36 0.30-0.82 x103/µL
Eo# 0.04-0.36 0.04-0.54 x103/µL
Baso# 0.01-0.08 0.01-0.08 x103/µL
RBC 3.93-5.22 4.63-6.08 x106/µL
HGB 11.2-15.7 13.7-17.5 g/dL
HCT 34.1-44.9 40.1-51.0 %
MCV 79.4-94.8 79.0-92.2 fL
MCH 25.6-32.2 25.7-32.2 pg
MCHC 32.2-35.5 32.3-36.5 g/dL
RDW-CV 11.7-14.4 11.6-14.4 %
RDW-SD 36.4-46.3 35.1-43.9 fL
PLT 182-369 163-337 x103/µL
K. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
L. Conclusion:
The submitted information in this premarket notification is complete and supports
a substantial equivalence decision.
7

[Table 1 on page 7]
Parameter	Females
n=133	Males
n=182	Units
WBC	3.98-10.04	4.23-9.07	x103/µL
Neut%	34.0-71.1	34.0-67.9	%
Lymph%	19.3-51.7	21.8-53.1	%
Mono%	4.7-12.5	5.3-12.2	%
Eo%	0.7-5.8	0.8-7.0	%
Baso%	0.1-1.2	0.2-1.2	%
Neut#	1.56-6.13	1.78-5.38	x103/µL
Lymph#	1.18-3.74	1.32-3.57	x103/µL
Mono#	0.24-0.36	0.30-0.82	x103/µL
Eo#	0.04-0.36	0.04-0.54	x103/µL
Baso#	0.01-0.08	0.01-0.08	x103/µL
RBC	3.93-5.22	4.63-6.08	x106/µL
HGB	11.2-15.7	13.7-17.5	g/dL
HCT	34.1-44.9	40.1-51.0	%
MCV	79.4-94.8	79.0-92.2	fL
MCH	25.6-32.2	25.7-32.2	pg
MCHC	32.2-35.5	32.3-36.5	g/dL
RDW-CV	11.7-14.4	11.6-14.4	%
RDW-SD	36.4-46.3	35.1-43.9	fL
PLT	182-369	163-337	x103/µL

--- Page 8 ---
8